April 2010
Volume 51, Issue 13
ARVO Annual Meeting Abstract  |   April 2010
Patient- and Physician-Reported Satisfaction Following Treatment With Bimatoprost 0.01% or Vehicle in Patients With Glaucoma or Ocular Hypertension (OHT)
Author Affiliations & Notes
  • E. R. Craven
    Glaucoma Consultants of Colorado, Parker, Colorado
  • T. Lin
    Biological Science, Allergan, Inc, Irvine, California
  • T. Mundorf
    Mundorf Eye Center, Charlotte, North Carolina
  • M. Tepedino
    Cornerstone Health Care, High Point, North Carolina
  • R. Frenkel
    University of Miami School of Medicine, Bacom Palmer Eye Institute, Stuart, Florida
  • J. Walt
    Mgr, Sr Global Health Outcomes,
    Allergan, Inc., Irvine, California
  • C.-C. Liu
    Allergan, Inc., Irvine, California
  • A. Batoosingh
    Allergan, Inc., Irvine, California
  • Footnotes
    Commercial Relationships  E.R. Craven, Allergan, C; Allergan, R; T. Lin, Allergan, E; T. Mundorf, Allergan, Pfizer, R; M. Tepedino, None; R. Frenkel, Allergan, Pfizer, Merck, Genentech, Regeneron, Ista, Macusight, Sirion, R; J. Walt, Allergan, E; C.-C. Liu, Allergan, E; A. Batoosingh, Allergan, E.
  • Footnotes
    Support  Allergan, Inc.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 170. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      E. R. Craven, T. Lin, T. Mundorf, M. Tepedino, R. Frenkel, J. Walt, C.-C. Liu, A. Batoosingh; Patient- and Physician-Reported Satisfaction Following Treatment With Bimatoprost 0.01% or Vehicle in Patients With Glaucoma or Ocular Hypertension (OHT). Invest. Ophthalmol. Vis. Sci. 2010;51(13):170.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

The efficacy of and safety of bimatoprost 0.01% has been reported in a phase 2 study of patients with glaucoma or OHT whose intraocular pressure (IOP) was adequately controlled with latanoprost. The purpose of this analysis was to evaluate patient- and physician-reported outcomes with treatment in that study.


In this double-masked, multicenter, parallel-group study, 222 patients were enrolled. The mITT population consisting of randomized and treated patients who had the primary safety variable, macroscopic hyperemia, evaluated at baseline and Month 1 visits included 147 and 71 patients randomized (2:1) to once-daily bimatoprost 0.01% or vehicle, respectively. Patients assessed acceptability of treatment by a series of 6 questions: 2 relating to willingness to continue treatment and 4 relating to eye appearance. Physicians answered 2 questions regarding willingness to continue use of study medication. Wilcoxon rank-sum test was used to compare groups.


After 1 month of treatment, a statistically significant difference was observed in patients’ or physicians’ response of receiving or prescribing the randomized treatment in 4 categories (P<.001, see Table below) Change in eye appearance was reported by 7 (5%) patients in the bimatoprost arm and by 4 (6%) patients in the vehicle arm.


Patient and physician acceptability of treatment significantly favored bimatoprost over vehicle.  

Clinical Trial:

www.clinicaltrials.gov NCT00538304

Keywords: clinical (human) or epidemiologic studies: outcomes/complications 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.